8-K: Profusa Inc. Amends Asset Purchase Agreement

Profusa Inc. has amended its Asset Purchase Agreement with Bio Insights LLC, removing provisions for management stock issuance.

Summary

• Profusa Inc. entered into a First Amendment to an Asset Purchase Agreement with Bio Insights LLC on May 22, 2026.
• This amendment modifies the original agreement dated April 21, 2026, concerning the acquisition of know-how assets related to Bio Insights LLC's PanOmics Assay.
• The aggregate purchase price for these assets is $30,000,000, to be paid in Series A Convertible Preferred Stock.
• The key change in the amendment is the deletion of Section 4.6 (Management Shares) and all related references.
• This section previously stipulated the issuance of 12% of the company's fully diluted common stock to management for retention purposes.
• The amendment removes this provision entirely, including the requirement for Compensation Committee approval.
• The original Asset Purchase Agreement remains in effect, except as expressly amended.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily concerns a procedural amendment to an existing agreement without significant new financial disclosures or strategic shifts.

Positives

• Streamlines the asset purchase agreement by removing a potentially complex stock issuance component for management.
• Clarifies the terms of the acquisition of the PanOmics Assay know-how assets.

Negatives

• The removal of management shares could potentially impact executive retention if not otherwise addressed.
• The specific reasons for removing the management share provision are not detailed, leaving room for speculation.

Risks

• Potential impact on executive morale and retention due to the removal of the management share incentive.
• Uncertainty regarding alternative retention strategies for key management personnel.
• The amendment could introduce unforeseen complexities if not fully integrated into ongoing operations.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the amendment to the existing agreement.

Management Comments

• The amendment deletes Section 4.6 (Management Shares) in its entirety.
• The amendment deletes the provision for the issuance of an aggregate number of shares of the Company's common stock equal to twelve percent (12%) of the fully diluted shares outstanding immediately following the Closing and any related equity financing, for the retention of the Company's Chief Executive Officer and Chief Financial Officer.

Industry Context

StockSavvy.ai notes that amendments to asset purchase agreements, particularly those involving the removal of management incentives, can signal shifts in deal structuring or internal strategic priorities within the biotechnology and drug discovery sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: The removal of management stock issuance may affect future dilution, though the exact impact depends on the conversion of preferred stock and any subsequent equity financing.
• Management: Key executives (CEO and CFO) may have altered retention incentives due to the removal of the planned stock grant.
• Creditors: No immediate impact is indicated.

Next Steps

• The Asset Purchase Agreement, as amended, remains in full force and effect.
• The acquisition of the PanOmics Assay know-how assets is expected to proceed under the amended terms.

Key Dates

Keywords

Asset Purchase Agreement Amendment, Profusa Inc., Bio Insights LLC, PanOmics Assay, Management Shares, Preferred Stock, Intellectual Property, Drug Discovery